Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis
Summary
Parkev presents a bullish thesis for Eli Lilly, focusing on the company's explosive growth driven by its weight loss treatments, Zepbound and oral GLP-1 pills. Despite entering the market after some competitors, Eli Lilly has already captured over 30% of new patient starts in the oral GLP-1 segment. Parkev highlights a study showing that Zepbound leads to significant medical cost savings—up to $600 per month after a year—which strengthens the long-term value proposition for patients and healthcare providers.
Financially, Eli Lilly is performing at a record level. Parkev points out that revenues have surged to $80 billion, a nearly tenfold increase in less than a decade, while operating margins have reached a historic 49.7%. Parkev credits this success to the company's strategy of outinvesting competitors like Pfizer and Novo Nordisk in research and development. This high R&D intensity suggests that Eli Lilly will continue to innovate and find new revenue streams even after the current weight loss drug boom matures.
Mentioned Stocks
Reasoning: Parkev references Pfizer as a peer in the pharmaceutical industry, using them as a benchmark to show that Eli Lilly's higher R&D spending and more effective operations are leading to superior financial results.
Reasoning: Parkev believes Eli Lilly is undervalued at a forward P/E of 24, especially given its massive revenue growth and 49.7% operating margins. Parkev's valuation model suggests a target price of $1,494, providing a 30% upside from the current $1,151 price point. Parkev personally bought the stock earlier this year and maintains a high-conviction buy rating.
Reasoning: Parkev mentions Novo Nordisk as a primary competitor in the booming weight loss drug market but notes that Eli Lilly is currently outperforming them in terms of R&D investment as a percentage of revenue.